Ernexa Therapeutics annual gross margin
2023
2024
Ernexa Therapeutics Gross Margin Growth & History (ERNA)
Ernexa Therapeutics's gross margin was 83.51% for fiscal 2024.
View full Ernexa Therapeutics company overviewErnexa Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 83.51% | +330.56 pp |
| 2023 | 2023-12-31 | −247.06% | — |
Ernexa Therapeutics quarterly gross margin
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | 100.00% | — |
| Q3 2024 | 2024-09-30 | 112.32% | +247.61 pp |
| Q2 2024 | 2024-06-30 | −102.13% | — |
| Q1 2024 | 2024-03-31 | −29.79% | — |
| Q3 2023 | 2023-09-30 | −135.29% | — |
Ernexa Therapeutics gross margin trends
Between the periods ended 2023-12-31 and 2024-12-31, Ernexa Therapeutics's gross margin increased from −247.06% to 83.51%, a change of +330.56 percentage points. The latest reported quarter, Q4 2024, shows 100.00%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ernexa Therapeutics source filings ↗